On October 8, 2025, Zura Bio Ltd announced that CEO Robert Lisicki is taking a medical leave of absence starting October 10, 2025, and Kim Davis will serve as interim CEO. This is considered a significant event from an equity investor's perspective and has a neutral sentiment.